Navigation Links
Independent Review Organizations Poised to Help Reduce Rising Healthcare Cost
Date:2/4/2008

LANSDALE, Pa., Feb. 4 /PRNewswire/ -- According to the National Coalition on Health Care, the increasing cost of health care outstrips both wages and inflation. Each year premiums rise at almost double-digit rates. If this continues, healthcare costs will rise from five percent of the GNP to 13 percent by 2050.

Within the healthcare industry, independent review organizations (IROs) offer hope for reducing healthcare costs. IROs act as third-party medical review resources providing unbiased medical opinions to support effective decision making for health plans and other payers. Basing decisions on medical evidence and the detailed facts in each case, IROs deliver conflict-free decisions that help clinical and claims managers allocate healthcare resources better and reduce waste.

"We believe IROs play a key role in reducing healthcare costs," said Joyce Muller, NAIRO president. "While they are little known, IROs exist to assure that people paying for health care get what they've paid for and health insurers only pay for medically necessary treatments."

This election year candidates from both parties are proposing solutions to the healthcare problem. "Greater attention is focused on keeping the escalating costs of healthcare down, and the effective use of IRO's contribute to that," Muller said.

IROs can help health plan providers and payers reduce costs by assisting with decisions like these:

-- Ensure compliance with state mandates for appeals and medical necessity

denials

-- Help payers meet Dept. of Labor (DOL) and Employee Retirement Income

Security Act of 1974 (ERISA) compliance guidelines

-- Determine when a treatment is needed medically

-- Decide whether a treatment is experimental based on the latest medical

literature

-- Decide if health plan language is outdated or ambiguous

-- Investigate fraudulent claims

-- Explore patient safety and quality-of-c
'/>"/>

SOURCE NAIRO
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the CL Seal of Approval a Worthless, Paid-For Advertising Gimmick
2. PCMA: New CBO Analysis Confirms Independent Pharmacy Collective Bargaining Legislation Increases Costs for Consumers and Payors
3. PCMA: New Study on Independent Pharmacy Reimbursements Will Raise Eyebrows on Capitol Hill
4. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
5. China Sky One Medical Appoints Independent Auditor
6. AMA Commends Independent Health for Joining Industry Shift on Physician Performance Measurement
7. PCMA Launches New Print Ad Campaign Highlighting Costs Associated With the Independent Drugstore Lobbys Agenda
8. In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk
9. Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics
10. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
11. Medical Services Receives Independent Test Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Executive Leadership and CEO Announced for BiPar Sciences 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 1Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 2Caldolor 28R 29 28Ibuprofen 29 Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 6465 3Sarnova Expands Senior Management Team 6463 1Sarnova Expands Senior Management Team 6463 2Proteon Initiates Second Phase 1 2 Clinical Study of PRT 201 in Hemodialysis Patients 6461 1Proteon Initiates Second Phase 1 2 Clinical Study of PRT 201 in Hemodialysis Patients 6461 2